Clinical Trial Update: A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [Phase 1]

View source ↗

Summary

This Clinical Trial Update reports on a Phase 1 single-ascending and repeated-dose study of LY3849891 in participants with MASLD and MASH, which is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• LY3849891

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Phase 1 | Status: ACTIVE_NOT_RECRUITING